Trial Profile
A Phase 2 Study of Lapatinib in Combination with Trastuzumab in Patients with HER2-Positive, Metastatic Breast Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Dec 2023
Price :
$35
*
At a glance
- Drugs Lapatinib (Primary) ; Trastuzumab
- Indications Advanced breast cancer; HER2 positive breast cancer
- Focus Therapeutic Use
- 19 May 2023 Planned End Date changed from 30 Dec 2022 to 30 Dec 2023.
- 15 Aug 2022 Planned End Date changed from 30 Apr 2022 to 30 Dec 2022.
- 14 Mar 2022 Planned End Date changed from 1 Dec 2021 to 30 Apr 2022.